Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of TMC278 (rilpivirine) in antiretroviral-naïve HIV-1 infected adolescents
2008-001696-30Phase 2Terminated
- Sponsor
- Tibotec
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilpivirine in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV), sponsored by Tibotec. Started Oct 2008; status: terminated.
02
Drugs
rilpivirine
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2008-001696-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001696-30.